$5.61 Earnings Per Share Expected for Regeneron Pharmaceuticals Inc (REGN) This Quarter

Wall Street analysts expect Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to post earnings of $5.61 per share for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have issued estimates for Regeneron Pharmaceuticals’ earnings. The lowest EPS estimate is $4.60 and the highest is $6.28. Regeneron Pharmaceuticals posted earnings of $5.23 per share during the same quarter last year, which suggests a positive year over year growth rate of 7.3%. The firm is scheduled to announce its next earnings results on Thursday, February 14th.

According to Zacks, analysts expect that Regeneron Pharmaceuticals will report full-year earnings of $21.49 per share for the current fiscal year, with EPS estimates ranging from $20.08 to $22.29. For the next fiscal year, analysts expect that the company will post earnings of $22.51 per share, with EPS estimates ranging from $19.08 to $26.69. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, November 6th. The biopharmaceutical company reported $5.87 earnings per share for the quarter, beating analysts’ consensus estimates of $4.94 by $0.93. Regeneron Pharmaceuticals had a net margin of 28.24% and a return on equity of 30.24%. The business had revenue of $1.66 billion during the quarter, compared to analysts’ expectations of $1.64 billion. During the same period last year, the business earned $3.99 earnings per share. The business’s revenue for the quarter was up 10.8% on a year-over-year basis.

A number of equities research analysts have weighed in on REGN shares. Oppenheimer set a $440.00 price target on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a research report on Sunday. Cantor Fitzgerald lifted their price target on shares of Regeneron Pharmaceuticals to $441.00 and gave the company a “neutral” rating in a research report on Monday, October 22nd. ValuEngine upgraded shares of Regeneron Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, September 6th. JPMorgan Chase & Co. reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, October 2nd. Finally, Leerink Swann lifted their price target on shares of Regeneron Pharmaceuticals from $506.00 to $512.00 and gave the company an “outperform” rating in a research report on Monday, October 1st. Two investment analysts have rated the stock with a sell rating, seventeen have issued a hold rating and five have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $408.42.

Shares of REGN opened at $382.61 on Friday. Regeneron Pharmaceuticals has a 1-year low of $281.89 and a 1-year high of $416.49. The stock has a market cap of $39.57 billion, a price-to-earnings ratio of 20.05, a P/E/G ratio of 1.57 and a beta of 1.36. The company has a quick ratio of 3.30, a current ratio of 4.04 and a debt-to-equity ratio of 0.09.

In related news, major shareholder Sanofi sold 104,552 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, September 6th. The shares were sold at an average price of $406.68, for a total value of $42,519,207.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Joseph L. Goldstein sold 2,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, September 24th. The stock was sold at an average price of $388.65, for a total transaction of $777,300.00. Following the completion of the transaction, the director now owns 13,000 shares of the company’s stock, valued at approximately $5,052,450. The disclosure for this sale can be found here. Insiders sold 108,552 shares of company stock valued at $44,081,027 in the last 90 days. Company insiders own 12.42% of the company’s stock.

A number of institutional investors have recently modified their holdings of the stock. Wrapmanager Inc. lifted its stake in Regeneron Pharmaceuticals by 9.9% in the second quarter. Wrapmanager Inc. now owns 1,440 shares of the biopharmaceutical company’s stock worth $497,000 after acquiring an additional 130 shares during the last quarter. Raymond James Financial Services Advisors Inc. lifted its stake in Regeneron Pharmaceuticals by 4.7% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 3,144 shares of the biopharmaceutical company’s stock worth $1,085,000 after acquiring an additional 141 shares during the last quarter. Traynor Capital Management Inc. lifted its position in shares of Regeneron Pharmaceuticals by 9.8% during the 2nd quarter. Traynor Capital Management Inc. now owns 1,631 shares of the biopharmaceutical company’s stock worth $572,000 after buying an additional 145 shares during the last quarter. Cito Capital Group LLC lifted its position in shares of Regeneron Pharmaceuticals by 4.3% during the 3rd quarter. Cito Capital Group LLC now owns 3,650 shares of the biopharmaceutical company’s stock worth $1,475,000 after buying an additional 150 shares during the last quarter. Finally, MUFG Securities EMEA plc lifted its position in shares of Regeneron Pharmaceuticals by 1.7% during the 2nd quarter. MUFG Securities EMEA plc now owns 9,031 shares of the biopharmaceutical company’s stock worth $3,116,000 after buying an additional 152 shares during the last quarter. Institutional investors own 67.24% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Story: How to interpret a stock’s beta number

Get a free copy of the Zacks research report on Regeneron Pharmaceuticals (REGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit